Meloxicam Solid Dispersion Composition for Faster Acute Pain Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam exhibits low solubility and slow absorption, leading to prolonged Tmax and inadequate treatment of acute pain, especially when administered under fasting conditions, and existing methods often involve cyclodextrin or complex formulations that may compromise stability.
Innovation Solution
A novel pharmaceutical composition of meloxicam is developed, comprising a solid dispersion with a hydrophilic polymer and alkalizing agents, embedding meloxicam in alkaline surroundings to maintain pH and prevent immediate precipitation, enhancing solubility and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If meloxicam is administered in pure form, then manufacturing is simple, but solubility is poor and absorption is slow
Solution Approach 1:
The patent uses a solid dispersion system combining meloxicam with hydrophilic polymers (such as HPMC, PEG, or PVP) to create a composite material. This composite structure improves the solubility and dissolution rate of meloxicam while maintaining manufacturing feasibility through conventional solid dispersion techniques.
Solution Approach 2:
The patent modifies the physical and chemical parameters of meloxicam by forming solid dispersions that change the drug's crystalline state to amorphous or molecularly dispersed state. This parameter change significantly enhances solubility and dissolution rate without complicating the manufacturing process.
2Speed
If meloxicam is administered under fasting conditions, then absorption is faster, but solubility is reduced due to low pH
Solution Approach 1:
The patent introduces an intermediary substance (hydrophilic polymer in solid dispersion) that mediates between the acidic gastric environment and meloxicam. The hydrophilic polymer creates a favorable microenvironment that protects meloxicam from precipitation in acidic conditions while maintaining enhanced dissolution.
Solution Approach 2:
The solid dispersion formulation changes the dissolution behavior of meloxicam by maintaining it in an amorphous or molecularly dispersed state within the hydrophilic polymer matrix. This parameter change allows the drug to remain soluble in acidic environments where pure meloxicam would precipitate.
3Reliability
If cyclodextrin is used to improve solubility, then bioavailability increases, but formulation complexity and stability issues arise
Solution Approach 1:
The patent replaces cyclodextrin with hydrophilic polymers that are more stable, easier to manufacture, and do not require complex inclusion complex formation. These alternative polymers provide similar or superior solubility enhancement without the stability and formulation complexity issues associated with cyclodextrin.
Solution Approach 2:
The patent creates solid dispersion composites using hydrophilic polymers that are inherently more stable and easier to work with than cyclodextrin inclusion complexes. This composite approach achieves enhanced bioavailability through simpler formulation and manufacturing processes.
4Device complexity
If pure meloxicam is used, then formulation is simple, but Tmax is prolonged and acute pain treatment is inadequate
Solution Approach 1:
The patent changes the physical state of meloxicam from crystalline to amorphous or molecularly dispersed within the hydrophilic polymer matrix. This parameter change dramatically increases the dissolution rate and reduces Tmax, enabling effective acute pain treatment while maintaining a relatively simple solid dispersion formulation.
Solution Approach 2:
The solid dispersion composite of meloxicam with hydrophilic polymer provides a balance between formulation simplicity and rapid drug release. The composite structure enables fast dissolution and absorption (reduced Tmax) without requiring complex formulation techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves rapid drug release and increased bioavailability, with reduced Tmax and higher Cmax, effectively treating acute pain even in fasting conditions without cyclodextrin derivatives.
Implementation Method 1
embedding meloxicam in alkaline surroundings to maintain pH and prevent immediate precipitation
Implementation Method 2
enhancing solubility and absorption
Implementation Method 3
comprising a solid dispersion with a hydrophilic polymer and alkalizing agents
Implementation Method 4
increased bioavailability, with reduced Tmax and higher Cmax
Data Source
AI summary
The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.